3 Key Takeaways
Plain English Summary- 01Core Finding
Delivered via cabergoline Suppresses Postpartum Breast Cancer by Enhancing Mammary Gland, this meta-analysis approach targets T cells.
- 02Study Evidence
Tested in a animal models + meta-analysis at the meta-analysis stage.
- 03Practical Meaning
Pooled evidence synthesis depends on the quality, heterogeneity, and potential publication bias of included studies.
What This Means for You
Notably, independent retrospective studies in two large cohorts of European women showed that cabergoline treatment was associated with a lower incidence of postpartum breast cancer, with a meta-analysis indicating an approximate meaningful reduction in risk. Our work underscores the importance of targeting postlactational involution as a strategy for the prevention of postpartum breast cancer and positions cabergoline as a novel, low-risk chemoprevention strategy.
The Discovery
Breast cancer that arises in the postpartum period often carries a poor prognosis and urgently requires chemoprevention strategies, particularly for women at elevated risk. Here, we report that a single post-lactation dose of cabergoline, a dopaminergic agonist that blocks prolactin secretion, delays the onset and reduces the incidence of postpartum mammary cancer in K14-Cre; Brca1F/F, Trp53F/F mice. In these mice, cabergoline treatment remodels the mammary gland by potentiating involution, reducing ductal area and proliferation, and reversing T cell exhaustion, potentially through modulation of ion channel expression.
How It Works, Simply
This oncology research focuses on T cells. Researchers evaluated it using an animal models + Meta-analysis at the meta-analysis stage of medical research.
3 Key Takeaways
Clinical Takeaways- 01Core Finding
Delivered via cabergoline Suppresses Postpartum Breast Cancer by Enhancing Mammary Gland, this meta-analysis approach targets T cells.
- 02Study Evidence
Tested in a animal models + meta-analysis at the meta-analysis stage.
- 03Practical Meaning
Pooled evidence synthesis depends on the quality, heterogeneity, and potential publication bias of included studies.
Biological Mechanism & Study Design
Study Design & Cohort
Animal models + Meta-analysis
Animal models + Meta-analysis · Meta-Analysis
Biological Pathway & Modality
T cells
Intervention: Cabergoline Suppresses Postpartum Breast Cancer by Enhancing Mammary Gland
Experimental Findings & Endpoints
Breast cancer that arises in the postpartum period often carries a poor prognosis and urgently requires chemoprevention strategies, particularly for women at elevated risk.
Here, we report that a single post-lactation dose of cabergoline, a dopaminergic agonist that blocks prolactin secretion, delays the onset and reduces the incidence of postpartum mammary cancer in K14-Cre; Brca1F/F, Trp53F/F mice. In these mice, cabergoline treatment remodels the mammary gland by potentiating involution, reducing ductal area and proliferation, and reversing T cell exhaustion, potentially through modulation of ion channel expression.
Clinical Translation & Practice Context
Notably, independent retrospective studies in two large cohorts of European women showed that cabergoline treatment was associated with a lower incidence of postpartum breast cancer, with a meta-analysis indicating an approximate meaningful reduction in risk.
Our work underscores the importance of targeting postlactational involution as a strategy for the prevention of postpartum breast cancer and positions cabergoline as a novel, low-risk chemoprevention strategy.
The Bottom Line · Clinical Pearl
“Our work underscores the importance of targeting postlactational involution as a strategy for the prevention of postpartum breast cancer and positions cabergoline as a novel, low-risk chemoprevention strategy.”
Published in Cancer Discovery · Current Stage: Meta-Analysis